Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.
Ryschich
Eduard
E
Department of Surgery, University of Heidelberg, Germany.
Jesnowski
Ralf
R
Ringel
Jörg
J
Harms
Walter
W
Fabian
Oliver V
OV
Saller
Robert
R
Schrewe
Michael
M
Engel
Alexander
A
Schmidt
Jan
J
Löhr
Matthias
M
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy; D019362:Cytochrome P-450 CYP2B1 / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding; D007069:Ifosfamide / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D008833:Microcirculation; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000628:therapy*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011829:Radiation Dosage; D051381:Rats; D011917:Rats, Inbred Lew; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D018906:Antineoplastic Agents, Alkylating; D018809:Proliferating Cell Nuclear Antigen; D014409:Tumor Necrosis Factor-alpha; D019362:Cytochrome P-450 CYP2B1; D007069:Ifosfamide